Phase II study of sunitinib as second-line treatment for advanced gastric cancer

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1449-1458

  Bang, Yung Jue ^a   Kang, Yoon Koo ^b   Kang, Won K ^c   Boku, Narikazu ^d   Chung, Hyun C ^e   Chen, Jen Shi ^f   Doi, Toshihiko ^g   Sun, Yan ^h   Shen, Lin ⁱ   Qin, Shukui ^j   Ng, Wai Tong ^k   Tursi, Jennifer M ^l   Lechuga, Maria J ^l   Lu, Dongrui Ray ^l   Ruiz Garcia, Ana ^l   Sobrero, Alberto ^m  

^a Seoul National University   (South Korea)

^b University of Ulsan   (South Korea)

^c Samsung Medical Center   (South Korea)

^d SHIZUOKA CANCER CENTER   (Japan)

^e Yonsei University College of Medicine   (South Korea)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h CANCER HOSPITAL   (China)

ⁱ PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^j Nanjing Bayi Hospital   (China)

^k PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^l PFIZER INC   (United States)

^m UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

Gastric cancer; Pharmacodynamics; Pharmacokinetics; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSCIOUSNESS DISORDER; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEART ARREST; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOTENSION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; VOMITING; ADENOCARCINOMA; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRROLES; QUALITY OF LIFE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 82955241985     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9438-y     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. doi:10.3322/canjclin. 55.2.74 (Pubitemid 40372904)
2. Inoue M, Tsugane S (2005) Epidemiology of gastric cancer in Japan. Postgrad Med J 81:419-424. doi:10.1136/pgmj.2004. 029330 (Pubitemid 41002579)
3. Jung KW, Yim SH, Kong HJ, Hwang SY, Won YJ, Lee JK, Shin HR (2007) Cancer survival in Korea 1993-2002: a populationbased study. J Korean Med Sci 22 Suppl: S5-S10. doi:10.3346/jkms.2007.22. S. S5
4. Scartozzi M, Galizia E, Verdecchia L, Berardi R, Antognoli S, Chiorrini S, Cascinu S (2007) Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother 8:797-808. doi:10.1517/ 14656566.8.6.797 (Pubitemid 46744768)
5. Wilson D, Hiller L, Geh JI (2005) Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 17:81-90. doi:10.1016/j.clon. 2004.10.006 (Pubitemid 40309884)
6. Wohrer SS, Raderer M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15:1585-1595. doi:10.1093/annonc/mdh422 (Pubitemid 39567288)
7. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168 (Pubitemid 27112884)
8. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909. doi:10.1200/JCO.2005.05.0245 (Pubitemid 46630593)
9. Ohtsu A (2008) Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 43:256-264. doi:10.1007/s00535-008-2177-6 (Pubitemid 351650035)
10. Drescher D, Moehler M, Gockel I, Frerichs K, Muller A, Dunschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T, Teufel A, Herzer K, Fischer T, Berger MR, Junginger T, Galle PR, Schimanski CC (2007) Coexpression of receptor-tyrosinekinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy? World J Gastroenterol 13:3605-3609 (Pubitemid 47162268)
11. Zhang H, Wu J, Meng L, Shou CC (2002) Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 8:994-998 (Pubitemid 35446408)
12. Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T (2006) Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12:3297-3305 (Pubitemid 43933772)
13. Katano M, Nakamura M, Fujimoto K, Miyazaki K, Morisaki T (1998) Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 227:365-371 (Pubitemid 28131017)
14. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858-863 (Pubitemid 26061277)
15. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM (1996) Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 2:1679-1684 (Pubitemid 26356351)
16. DOI T, Koizumi W, Siena S, Cascinu S, Ohtsu A, Michael M, Takiuchi H, Swaisland H, Gallagher N, Van Cutsem E (2003) Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 22: Abstract 1036.
17. Rojo F, Tabernero J, Albanell J, Van CE, Ohtsu A, DOI T, Koizumi W, Shirao K, Takiuchi H, Cajal S, Baselga J (2006) Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 24:4309-4316. doi:10.1200/JCO.2005.04.2424 (Pubitemid 46630789)
18. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201-5206. doi:10.1200/JCO.2006.08.0887 (Pubitemid 46631363)
19. Pinto C, Di FF, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510-517. doi:10.1093/annonc/mdl459 (Pubitemid 46359631)
20. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100:298-304. doi:10.1038/sj.bjc.6604861
21. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24:4922-4927. doi:10.1200/JCO.2006.07.1316 (Pubitemid 46630921)
22. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
23. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337 (Pubitemid 36109749)
24. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605. doi:10.1182/blood- 2002-07-2307 (Pubitemid 36857948)
25. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338. doi:10.1016/S0140-6736 (06) 69446-4 (Pubitemid 44528723)
26. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216. doi:10.1093/jnci/92.3.205
28. Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, Klamerus KJ (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17:353-358
29. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376. doi:10.1093/jnci/85.5.365 (Pubitemid 23073154)
30. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van CE, D'haese S, Coens C (2004) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 40:2260-2268. doi:10.1016/j.ejca.2007.07.005 (Pubitemid 39348876)
31. Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G (2003) Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G. O. I. M.). Anticancer Res 23:4219-4222. (Pubitemid 37474923)
32. Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang YK (2007) Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 37:936-941. doi:10.1093/jjco/hym123 (Pubitemid 351176485)
33. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y (2006) Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14-18. doi:10.1007/s10120-005-0351-6
34. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N (2007) A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer Res 27:2667-2671 (Pubitemid 47227980)
35. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM (2004) Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 34:8-13. doi:10.1093/jjco/hyh006 (Pubitemid 43118052)
36. Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, Bokemeyer C (1999) Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drugs 10:729-733 (Pubitemid 30015674)
37. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y (2009) Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27: abstr LBA4509.
38. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816. doi:10.1200/JCO.2007.14.5375
39. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced nonsmallcell lung cancer. J Clin Oncol 26:650-656. doi:10.1200/JCO.2007.13.9303 (Pubitemid 351264362)
40. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35. doi:10.1200/JCO.2005.02.2194 (Pubitemid 46630490)
41. DePrimo SE, Bello C (2007) Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol 18 Suppl 10:x11-9.: x11-x19. doi:10.1093/annonc/mdm409
42. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759. doi:10.1200/JCO.2006.07.3049 (Pubitemid 46797957)
43. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24. doi:10.1200/JCO.2005.02.2574 (Pubitemid 46630489)
44. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV (2007) Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13:2643-2650. doi:10.1158/1078-0432. CCR-06-0919 (Pubitemid 46788031)
45. Yoon SY, Kim SY, Cho YH, Chung HW, So Y, Lee HM (2009) Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT. Cancer Res Treat 41:100-103. doi:10.4143/crt.2009.41.2. 100